{"entity":{"id":"nct00841113","kind":"trial","name":"Abarelix Versus Goserelin Plus Bicalutamide in Patients With Advanced or Metastatic Prostate Cancer","aka":[],"tldr":"A phase 3 trial of Abarelix in Prostate cancer, run by Speciality European Pharma Limited, completed.","summary":"Abarelix Versus Goserelin Plus Bicalutamide in Patients With Advanced or Metastatic Prostate Cancer is a phase 3 interventional study registered as NCT00841113 by Speciality European Pharma Limited, with 177 participants recorded, started 1999-01 and reaching its primary completion in 2001-02. Interventions recorded: Abarelix, Goserelin plus Bicalutamide. Conditions recorded: Prostate Cancer.\n\nLinked to the drug Abarelix because the registry names it among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.","status":"completed","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT00841113","url":"https://clinicaltrials.gov/study/NCT00841113"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":["abarelix"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT00841113","phase":"3","setting":"Phase III Study of the Comparison of Abarelix Versus Goserelin Plus Bicalutamide in Patients With Advanced or Metastatic Prostate Cancer. A One Year Randomised, Open Label, Multi-Centre Phase III Trial.","sponsor":"Speciality European Pharma Limited","enrolled":177,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct00841113/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"drug":[{"id":"abarelix","kind":"drug","name":"Abarelix","route":"/drugs/abarelix/"}]}}